2 results about "Allogeneic graft" patented technology

Disclosed herein includes a method for treating antibody-mediated kidney allograft rejection, comprising treating a subject determined to suffer from antibody-mediated kidney allograft rejection more than 6 months after transplantation by administering an anti-CD38 antibody or antigen-binding fragment thereof (e.g., daratumumab, felzartamab, or isatuximab) to the subject; extracting cell-free DNA from a blood, plasma, serum or urine sample collected from the subject after conclusion of the treatment; quantifying an amount of donor-derived cell-free DNA, a percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, in the extracted DNA; and retreating the subject with an anti-CD38 antibody or antigen-binding fragment thereof if the amount of donor-derived cell-free DNA, the percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, exceed one or more threshold values.

Rapid recovery with extended ultra-oxygenated preservation (REUP) can ethically and cost-effectively improve recovery and transplant outcomes for donation after circulatory death (DCD) allografts. REUP can include a portable system, method, and specialized ultra-oxygenated solution(s). The portable system includes a flush circuit and at least one cannula connected to the DCD allograft for flushing the ultra-oxygenated solution into the in-situ DCD allograft. The flush circuit can include at least one reservoir for the ultra-oxygenated solution, a temperature control device, a pressure regulation system, optionally an oxygenator, and tubing for connecting components. The system is noted as easily portable and cost effective for use in many conditions, including environments where traditional recovery systems cannot be used. The methods and solution can be specialized depending on donor demographic information, previous surgeries, and / or allograft type.